Sign in →

Test ID: FIXKM Hemophilia B, F9 Gene Known Mutation, Whole Blood

Reporting Name

F9 Gene Known Mutation, B

Useful For

Diagnostic, targeted testing for hemophilia B when a mutation has been identified in a family member


Carrier testing of females in whom the familial F9 genotype is known

Testing Algorithm

Maternal cell contamination testing will be performed for all cord blood specimens. A maternal whole blood sample with an order for MATCC / Maternal Cell Contamination, Molecular Analysis, Blood is also required to perform this test. (See Specimen Required for more details.)


The following algorithms are available in Special Instructions:

-Hemophilia Carrier Testing Algorithm

-Hemophilia Testing Algorithm

Specimen Type

Whole blood

Additional Testing Requirements

Due to the complexity of testing non-peripheral blood, consultation with the laboratory is required for all cord blood samples. Order FIXKM / Hemophilia B, F9 Gene Known Mutation, Whole Blood on the cord blood specimen (only 1 sample tube required) and order MATCC / Maternal Cell Contamination, Molecular Analysis, Blood on the maternal specimen.

Necessary Information

Hemophilia B Patient Information is required, see Special Instructions. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.

Specimen Required


Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD) or blue top (sodium citrate)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send specimen in original tube.

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole blood Ambient (preferred) 7 days
  Frozen  7 days
  Refrigerated  7 days

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Performed weekly; Varies

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81403-Known familial variant not otherwise specified, for gene listed in Tier 1 or Tier 2, DNA sequence analysis, each variant exon

LOINC Code Information

Test ID Test Order Name Order LOINC Value
FIXKM F9 Gene Known Mutation, B 69483-6


Result ID Test Result Name Result LOINC Value
23763 F9 Known Mut Reason for Referral 42349-1
23764 F9 Known Mutation Method 85069-3
23765 F9 Known Mutation Result 38896-7
23766 F9 Known Mutation Interpretation 69047-9
37320 F9 Known Mutation Specimen Type 31208-2
23768 F9 Known Mutation Reviewed By 18771-6

Clinical Information

Hemophilia B, factor IX deficiency, is an X-linked recessive bleeding disorder with an incidence of about 1 per 30,000 live male births. It occurs as a result of mutations in the factor IX (F9) gene. As many as one-third of hemophiliacs have no affected family members, which reflects a high mutation rate in the F9 gene (ie, de novo mutations). Hemophilia B affects males; however, all male offspring from an affected male will be normal. Although all female offspring of affected males will be obligatory carriers, they rarely have symptomatic bleeding. In contrast, female offspring of female carriers of hemophilia B have a 50% chance of being carriers themselves, and each male offspring has a 50% chance of being affected.


Based on factor IX activity, hemophilia B is classified as severe (factor IX activity <1%), moderate (factor IX activity 1%-5%), or mild (factor IX activity >5%-40%). In males, low factor IX activity level establishes the diagnosis of hemophilia B. However, the wide range of normal factor IX activity precludes an accurate assessment of carrier status in females, thus making molecular testing essential in assessment of carrier status.


Inhibitors to factor IX activity are estimated to occur in 5% to 8% of patients, much less than that of hemophilia A. Inhibitor risk correlates with genotype and typically occurs in patients with either partial or total deletions of the F9 gene or in certain nonsense mutations that result in no circulating factor IX antigen. More recently, it has been observed that a subset of patients with such mutations may be at risk of experiencing anaphylactic reactions to the factor IX replacement therapy.


The interpretive report will include assay information, background information, and conclusions based on the test results.

Clinical Reference

1. Yoshitake S, Schach BG, Foster DC, et al: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985 July 2;24(14):3736-3750

2. Giannelli F, Green PM, Sommer SS, et al: Haemophilia B: database of point mutations and short additions and deletions. Eighth edition. Nucleic Acids Res 1998 Jan 1;26(1):265-268

3. Ketterling RP, Bottema CD, Phillips JA 3rd, et al: Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. Genomics 1991 Aug;10(4):1093-1096

4. Johnsen JM, Fletcher SN, Huston H, et al: Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv 2017 May;1(13):824-834 doi:10.1182/bloodadvances.2016002923

Analytic Time

21 days

Method Name

Polymerase Chain Reaction (PCR)/Sanger Sequencing

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
MATCC Maternal Cell Contamination, B Yes No


1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Mayo Clinic Laboratories | Hematology Catalog Additional Information: